SGLT2 inhibitors
( DrugBank: - / KEGG DRUG: - )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 208 | Corrected transposition of great arteries | 1 |
| 210 | Single Ventricle | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 215 | Tetralogy of Fallot | 1 |
208. Corrected transposition of great arteries
Clinical trials : 2 / Drugs : 2 - (DrugBank : 0) / Drug target gene : 0 - Drug target pathway : 0
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
210. Single Ventricle
Clinical trials : 61 / Drugs : 70 - (DrugBank : 25) / Drug target genes : 35 - Drug target pathways : 78
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
215. Tetralogy of Fallot
Clinical trials : 28 / Drugs : 55 - (DrugBank : 19) / Drug target genes : 16 - Drug target pathways : 50
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|